Top Markets
#1 Black Phoenix Black Phoenix +25.07%
#2 Boba Network Boba Network +21.29%
#3 Cysic Cysic +14.72%
#4 DAO Maker DAO Maker +14.48%
#5 Strategic Oil Supply Strategic Oil Supply +14.41%
#6 Solv Protocol SolvBTC Jupiter Solv Protocol SolvBTC Jupiter +14.33%
#7 FLOCK FLOCK +13.80%
#8 Bedrock Bedrock +12.26%
#9 Bitway Bitway +12.04%
#10 Freedom of Money Freedom of Money +8.34%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classificação em ações #161
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Preço da ação
$454.00
Valor de mercado
$115.32B
Variação (1 dia)
-0.88%
Variação (1 ano)
-9.78%
País
US
Negociar Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Healthcare
Receita da Vertex Pharmaceuticals Incorporated (VRTX)
Receita em Dec 2025 TTM: $12.04B
De acordo com os últimos relatórios financeiros da Vertex Pharmaceuticals Incorporated, a receita atual da empresa (TTM) é $12.04B. Em 2024, a empresa obteve uma receita de $11.02B um aumento em relação a a receita do ano 2023, que foi de $9.87B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Vertex Pharmaceuticals Incorporated de 2000 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $12.04B 0.31%
2025 $12.00B 8.90%
2024 $11.02B 11.66%
2023 $9.87B 10.51%
2022 $8.93B 17.91%
2021 $7.57B 22.06%
2020 $6.21B 49.07%
2019 $4.16B 36.59%
2018 $3.05B 22.46%
2017 $2.49B 46.20%
2016 $1.70B 64.89%
2015 $1.03B 77.86%
2014 $580.42M -52.11%
2013 $1.21B -20.63%
2012 $1.53B 8.25%
2011 $1.41B 883.91%
2010 $143.37M 40.49%
2009 $102.05M -41.85%
2008 $175.50M -11.81%
2007 $199.01M -8.02%
2006 $216.36M 34.47%
2005 $160.89M 56.63%
2004 $102.72M 48.56%
2003 $69.14M -57.08%
2002 $161.09M -3.82%
2001 $167.49M 114.38%
2000 $78.13M 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 302.35%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 19.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -24.56%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 30.38%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -54.39%
NL